Medical Cannabis for Chronic Pain UK — Complete Guide

Chronic pain affects more than 28 million adults in the UK, and for a growing number of patients, medical cannabis is becoming a legitimate part of their treatment plan. Whether you are dealing with neuropathic pain, inflammatory conditions or persistent musculoskeletal discomfort, understanding how cannabis-based medicines work and how to access them is essential.

Neuropathic vs Inflammatory Pain: Understanding the Difference

The World Health Organization defines chronic pain as pain lasting longer than three months that significantly affects daily functioning. Within this broad category, two distinct mechanisms are particularly relevant to medical cannabis treatment.

Neuropathic pain arises from damage or dysfunction in the nervous system itself. Conditions such as diabetic neuropathy, post-herpetic neuralgia, complex regional pain syndrome and chemotherapy-induced peripheral neuropathy all fall into this category. Patients typically describe burning, shooting or electric-shock sensations. The endocannabinoid system plays a direct role in modulating nociceptive signalling in the spinal cord, which is why THC and CBD can offer relief where conventional analgesics have failed.

Inflammatory pain stems from tissue damage or immune-mediated inflammation — arthritis, fibromyalgia and inflammatory bowel disease being common examples. CBD has demonstrated anti-inflammatory properties via its interaction with CB2 receptors and TRPV1 channels, making it particularly relevant for this pain subtype. Many patients find that a balanced THC:CBD product addresses both the inflammation and the associated sleep disruption.

Flower vs Oil: Choosing the Right Formulation

Medical cannabis in the UK is available in two primary forms: dried flower for vaporisation and oil-based preparations. Each has distinct pharmacokinetic profiles that matter for pain management.

Dried flower vaporised at 170 to 210 degrees Celsius delivers cannabinoids rapidly into the bloodstream via the lungs, with onset within five to fifteen minutes and peak effects at around thirty minutes. This makes it well-suited to breakthrough pain — acute flares that need fast relief. UK-licensed clinics such as Alternaleaf, Mamedica and Lyphe commonly prescribe high-THC flower strains from MHRA-approved suppliers including Rokshaw, Aurora and Transvaal.

Oils administered sublingually absorb through the mucous membranes under the tongue, with onset between thirty and ninety minutes and a longer duration of four to eight hours. They are preferred for background pain management, providing steadier plasma levels without the peaks and troughs associated with inhalation. CBD-dominant and balanced 1:1 oils are commonly prescribed for daytime use, with higher-THC preparations reserved for evening or bedtime.

Your prescribing clinician will help you identify the right formulation based on your pain profile. You can compare prices across available products on our platform.

Accessing Medical Cannabis for Chronic Pain in the UK

Since Schedule 2 rescheduling in November 2018, UK specialist doctors registered with the General Medical Council can legally prescribe cannabis-based medicines (CBPMs) for chronic pain that has not responded to two or more conventional treatments. The MHRA regulates all licensed products, though many CBPMs are prescribed as specials — unlicensed medicines prepared by MHRA-registered pharmacies.

The typical patient pathway involves an initial consultation with a GMC-registered specialist, followed by a written prescription dispensed by a UK-licensed pharmacy. Costs vary significantly: UK licensed clinics such as Alternaleaf offer subscription models from £5 per month with low consultation fees, while clinics like Releaf charge around £99 for initial appointments. Monthly product costs typically range from £80 to £250 depending on volume and formulation.

Chronic pain accounts for an estimated 60 to 70 per cent of all active medical cannabis prescriptions in the UK. Patients who have tried and failed at least two conventional pain medicines — including anticonvulsants, antidepressants with analgesic properties or opioid analgesics — are generally considered good candidates. Explore qualifying conditions to see whether your specific diagnosis may be eligible.

Side Effects, Monitoring and Long-Term Use

Like all medicines, cannabis-based preparations carry potential side effects that patients and clinicians must monitor. The most commonly reported are dry mouth, dizziness, mild sedation and short-term memory impairment — most of which are dose-dependent and reduce as the body adapts during the titration phase. A small proportion of patients experience heightened anxiety, particularly with high-THC products taken in larger doses; reducing the dose or switching to a higher-CBD ratio typically resolves this.

Long-term use requires regular clinical review. UK clinics prescribing for chronic pain typically schedule three-monthly follow-up appointments to assess ongoing efficacy, tolerability and whether the dose remains appropriate. Blood pressure and heart rate are occasionally monitored in older patients or those with cardiovascular risk factors, as THC can cause transient increases in both. Patients are also advised not to drive or operate heavy machinery within several hours of using THC-containing products, in line with current DVLA guidance on controlled drug impairment.

For patients with chronic pain considering long-term CBPM use, the safety profile compares favourably to high-dose opioids: there is no risk of fatal respiratory depression from cannabis, and physical dependence, while possible, is less severe than opioid dependence. Clinical guidelines recommend periodic reassessment of the benefit-risk ratio, with dose reductions or treatment breaks encouraged where ongoing high-dose use is not clearly justified by symptom control. Most UK clinics provide a secure patient portal where you can log symptoms between appointments, helping to build the evidence base for prescription continuation.